S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
LON:BXP

Beximco Pharmaceuticals - BXP Share Forecast, Price & News

GBX 40
-1.50 (-3.61%)
(As of 03/22/2023 04:39 PM ET)
Add
Compare
Today's Range
37.50
▼
40
50-Day Range
40
▼
51
52-Week Range
37.50
▼
105
Volume
76,496 shs
Average Volume
71,366 shs
Market Capitalization
£178.44 million
P/E Ratio
500.00
Dividend Yield
7.50%
Price Target
N/A

BXP stock logo

About Beximco Pharmaceuticals (LON:BXP) Stock

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

Receive BXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beximco Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BXP Stock News Headlines

March 12, 2023 | msn.com
Beximco to produce medicines in Saudi Arabia from next year
February 11, 2023 | fool.co.uk
Beximco Pharmaceuticals
March 22, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
October 26, 2022 | wsj.com
Beximco Pharmaceuticals Ltd.
September 8, 2022 | investing.com
Beximco Pharmaceuticals Ltd (BXPH)
January 20, 2022 | nasdaq.com
Beximco Pharma Granted Sub-license To Produce Molupiravir - Quick Facts
November 9, 2021 | nasdaq.com
Beximco Pharma Launches Generic Molnupiravir In Bangladesh To Treat Symptomatic COVID-19
August 2, 2021 | barrons.com
Beximco Pharmaceuticals Ltd. GDR
March 22, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 1, 2021 | lse.co.uk
Beximco Pharma Share Chat
March 26, 2021 | proactiveinvestors.com
Beximco Pharmaceut - Price Monitoring Extension
February 4, 2021 | nasdaq.com
India's Serum delays vaccines for private sale in Bangladesh; focus on state campaigns
January 29, 2021 | msn.com
Colombia police seize boxes of remdesivir in border city
January 22, 2021 | lse.co.uk
Beximco Pharma Share News (BXP)
January 21, 2021 | msn.com
Sanofi selects Beximco as potential buyer
January 21, 2021 | lse.co.uk
Beximco Snaps Up 55% Holding In Sanofi's Bangladesh Arm
January 11, 2021 | msn.com
Coronavirus vaccine rollout from February’s first week
January 8, 2021 | marketwatch.com
Respiratory Inhaler Devices Market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis 2020-2026
January 7, 2021 | msn.com
Govt approves emergency use of Covishield
January 5, 2021 | msn.com
DGHS finalises Covid-19 vaccination guidelines
January 5, 2021 | marketwatch.com
Large Volume Parenterals (LVP) Market Share, Analysis, CAGR and Value Chain Study, Showing Impressive Growth by 2026
January 4, 2021 | msn.com
Bangladesh drug regulator approves import of Oxford-SII's Covid vaccine
December 29, 2020 | msn.com
Private sector may be allowed to import Covid vaccine
December 17, 2020 | marketwatch.com
Respiratory Inhaler Devices Market 2020 Current and Future Trend Scenario Explored In New Latest Research Report
November 24, 2020 | sg.finance.yahoo.com
Beximco Pharmaceuticals Limited (BXP.L)
November 24, 2020 | ca.finance.yahoo.com
Beximco Pharmaceuticals Limited (R2WA.SG)
November 24, 2020 | marketwatch.com
State gives nod to Covid drug despite WHO's warning
See More Headlines
Receive BXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beximco Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:BXP
CUSIP
N/A
CIK
N/A
Web
www.beximco-pharma.com
Phone
+880-2-58611001
Fax
N/A
Employees
5,500
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.08
Trailing P/E Ratio
500.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
12.38%
Pretax Margin
N/A
Return on Equity
10.22%
Return on Assets
6.30%

Debt

Debt-to-Equity Ratio
25.16
Current Ratio
1.48
Quick Ratio
0.37

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
446,110,000
Free Float
N/A
Market Cap
£178.44 million
Optionable
Optionable
Beta
0.75

Key Executives

  • Mr. Md. Nazmul Hassan MP
    MD & Director
  • Mr. Mohammad Ali Nawaz
    Chief Financial Officer
  • Mr. S. M. Rabbur Reza
    Chief Operating Officer
  • Mr. Jamal Ahmed Choudhury
    Director of Accounts & Fin.
  • Mr. Rizvi Ul Kabir
    Director of Marketing
  • Mr. M. A. Arshad Bhuiyan
    Gen. Mang. of HR
  • Mr. Zakaria Seraj Chowdhury
    Head of Distribution Services & Director of International Marketing
  • Mr. Mohammad Asad Ullah FCS
    Company Sec. & Exec. Director
  • Mr. Prabir Ghose
    Exec. Director of Quality Assurance

Key Competitors

View All Competitors













BXP Stock - Frequently Asked Questions

How have BXP shares performed in 2023?

Beximco Pharmaceuticals' stock was trading at GBX 54 at the start of the year. Since then, BXP shares have decreased by 25.9% and is now trading at GBX 40.
View the best growth stocks for 2023 here.

Is Beximco Pharmaceuticals a good dividend stock?

Beximco Pharmaceuticals (LON:BXP) pays an annual dividend of GBX 3 per share and currently has a dividend yield of 6.86%. BXP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,750.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

What is Beximco Pharmaceuticals' stock symbol?

Beximco Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "BXP."

How do I buy shares of Beximco Pharmaceuticals?

Shares of BXP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Beximco Pharmaceuticals' stock price today?

One share of BXP stock can currently be purchased for approximately GBX 40.

How much money does Beximco Pharmaceuticals make?

Beximco Pharmaceuticals (LON:BXP) has a market capitalization of £178.44 million.

How many employees does Beximco Pharmaceuticals have?

The company employs 5,500 workers across the globe.

How can I contact Beximco Pharmaceuticals?

Beximco Pharmaceuticals' mailing address is 19 Dhanmondi R/A, Road No. 7, DHAKA, 1205, Bangladesh. The official website for the company is www.beximco-pharma.com. The company can be reached via phone at +880-2-58611001.

This page (LON:BXP) was last updated on 3/22/2023 by MarketBeat.com Staff